WO2024116086 - HETEROCYCLIC COMPOUND AND USE THEREOF
National phase entry:
Publication Number
WO/2024/116086
Publication Date
06.06.2024
International Application No.
PCT/IB2023/062016
International Filing Date
29.11.2023
Title **
[English]
HETEROCYCLIC COMPOUND AND USE THEREOF
[French]
COMPOSÉ HÉTÉROCYCLIQUE ET SON UTILISATION
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
KINA, Asato
IKEDA, Zenichi
KONO, Mitsunori
OGURO, Yuya
KUBO, Osamu
YAMASHITA, Toru
TAKAMI, Kazuaki
YUKAWA, Takafumi
SETO, Masaki
KAMATA, Makoto
SATO, Kenjiro
MURAKAMI, Masataka
SASAKI, Yusuke
REYNOLDS, Matthew Thomas
NAKAMURA, Minoru
KAMEI, Taku
KAKEI, Hiroyuki
YAMAGUCHI, Fumie
OHASHI, Tomohiro
KOJIMA, Takuto
KAKEGAWA, Keiko
PÜNNER, Florian
NAKAMURA, Shinji
MORISHITA, Nao
HIDAKA, Tadashi
TAKASHIMA, Sachie
TANIGUCHI, Takahiko
Priority Data
63/385,598
30.11.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4603 | |
| EPO | Filing, Examination, Granting | 30193 | |
| Japan | Filing, Examination, Granting | 3102 | |
| South Korea | Filing, Examination, Granting | 3926 | |
| USA | Filing, Examination, Granting | 12740 |
Total:
54,564
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.[French]
La présente invention concerne un composé hétérocyclique ayant une activité agoniste du récepteur de type 2 de l'orexine. L'invention concerne un composé de formule (I) : dans laquelle chaque symbole est tel que décrit dans la description, ou un sel de celui-ci a une activité agoniste du récepteur de type 2 de l'orexine, et est utile en tant qu'agent pour la prophylaxie ou le traitement de la narcolepsie.